Yeah I’m not sure of the distinction between the different classifications - it does sound like there is overlap. Fast track allows more interaction, think priority review is for a yes/no for approval more quickly is my quick reading of it - someone else can add more nuance if they’d like to.
the point I was making is I don’t think Imugene will get a voucher - it’s for tropical, rare paediatric, and medical countermeasures only, other things for cancer I guess, like accelerated approval etc?
Media Thread, page-11224
-
- There are more pages in this discussion • 3,521 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
